NCT03966651
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03966651
Title A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. (NEUROBLU 02)
Acronym NEUROBLU 02
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Institut Claudius Regaud
Indications
Therapies
Age Groups: adult | child
Covered Countries FRA

Facility Status City State Zip Country Details
CHU Angers Angers France Details
CHU Besançon Besançon France Details
CHU Pellegrin Bordeaux France Details
CHU Dijon Dijon France Details
CHU de Grenoble Grenoble France Details
Centre Oscar Lambret Lille France Details
Centre Léon Bérard Lyon France Details
Hopital Arnaud de Villeneuve Montpellier France Details
CHU Nancy Nancy France Details
CHU Nantes Nantes France Details
CHU Reims Reims France Details
CHU Strasbourg Strasbourg France Details
CHU de Toulouse - Hôpital des enfants Toulouse France Details
IUCT-O Toulouse France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field